Lederfolin (Calcium Levofolinate)

Calcium levofolinate is a reduced form of folic acid that bypasses the dihydrofolate reductase step. By directly supplying tetrahydrofolate, it restores the cellular folate pool needed for DNA synthesis and repair, allowing healthy cells to recover from the effects of antifolate drugs.

The dosage of Lederfolin is determined by the prescribing clinician based on the specific indication, patient weight, renal function, and the concurrent chemotherapy regimen. Only a qualified health professional should set the dose and schedule.

Safety data for Lederfolin in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified health care provider.

To order Lederfolin, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lederfolin provides calcium levofolinate, a stable reduced folate that bypasses dihydrofolate reductase, similar to other agents such as leucovorin. Clinical choice often depends on formulation, regulatory status, and supplier availability; Lederfolin offers EU‑sourced quality and GNH India's global distribution network.

Lederfolin should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children.

Lederfolin is administered orally as directed by the prescribing clinician. It is typically taken with water, and the timing relative to methotrexate or other chemotherapy agents is coordinated to maximize rescue effectiveness.

Serious adverse reactions include anaphylaxis, severe neutropenia, hepatic dysfunction, and rare skin conditions such as Stevens‑Johnson syndrome. Patients should be monitored for signs of allergic reaction, blood count changes, and liver enzyme elevations during therapy.

Lederfolin should be avoided in patients with known hypersensitivity to calcium levofolinate or any excipients, and in those with severe renal or hepatic impairment unless a specialist determines that benefits outweigh risks. Pregnant or breastfeeding women should use it only under strict medical supervision.